UNSPSC 51162608: Benproperine phosphate

This classification denotes an antitussive agent with the molecular formula C21H27NO.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S831Z48C5W, chemically known as piperidine, 1-(1-methyl-2-((alpha-phenyl-o-tolyl)oxy)ethyl)-, phosphate but more generally known as benproperine phosphate, which bears US NIH Compound Identifier 167811. European Medicines Agency schedules Benproperine phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00705MIG.

Most nations, for tariff and trade purposes, schedule benproperine phosphate under HS 29333999 and SITC 51574. As of Q4 2014, BENPROPERINE PHOSPHATE remains US FDA's Preferred Term for this commodity. SMILES: CC(COC1CCCCC1CC2CCCCC2)N3CCCCC3.OP(=O)(O)O.

UNSPSC 51162608 Benproperine phosphate is a Commodity code that does not align with the recent state and local procurement activity posted under it. Seminole County, Florida's July 2026 IFB sought naloxone and drug deactivation systems for community health initiatives, while the Minnesota Multistate Cooperative Purchasing Alliance's January 2026 RFP addressed generic multi-source pharmaceuticals and OTC products through established authorized wholesalers — neither solicitation involves benproperine phosphate procurement. The code shows no recent activity that reflects its nominal scope, suggesting either sparse demand for this specific pharmaceutical product line among state and local buyers or potential miscoding in the procurement systems posting these opportunities.

The two documented opportunities span different issuing-body types and geographies. Seminole County represents a single county health procurement, while MMCAP represents a multi-state cooperative purchasing vehicle administered by the Minnesota Department of Administration covering participating state and local facilities across Minnesota and Oregon. Activity is concentrated in Florida and the upper Midwest, but neither opportunity relates to benproperine phosphate acquisition. Vendors pursuing this code should verify current demand signals before investing in capability development, as state and local governments appear to source pharmaceutical products through broader generic-product contracts or disease-specific procurement (such as naloxone for overdose response) rather than targeting individual active pharmaceutical ingredients under this commodity classification.